Engineering ArtE2, a polycationic peptide-fused Bacillus endolysin, expands antibacterial activity to Escherichia coli while retaining potency against Staphylococcus aureus
This study reports the engineering of ArtE2, a polycationic peptide-fused and mutated variant of *Bacillus altitudinis* endolysin, which successfully expands antibacterial activity to *Escherichia coli* while retaining potency against *Staphylococcus aureus*.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
For decades, the fight against bacterial infections has relied on a shrinking arsenal of antibiotics, a situation that has grown increasingly urgent as bacteria evolve to resist these drugs. A promising alternative lies in nature's own viral hunters: bacteriophages. These viruses infect bacteria and, in their final act of reproduction, release special enzymes called endolysins. These enzymes act like precise molecular scissors, cutting open the bacterial cell wall to release new viruses. While these scissors work brilliantly against many bacteria, they face a significant hurdle when trying to attack a specific group known as Gram-negative bacteria. These organisms possess an extra outer shield that blocks most endolysins from reaching their target, rendering the natural enzymes ineffective against them. Scientists have long sought a way to modify these enzymes, perhaps by attaching a small, positively charged tag that could help them punch through this outer barrier, thereby expanding their reach to include dangerous Gram-negative pathogens like Escherichia coli.
In a recent study, researchers set out to test this idea by engineering a new version of a naturally occurring enzyme. They started with an endolysin derived from a bacterium called Bacillus altitudinis, which they knew was already effective at destroying Staphylococcus aureus, a common Gram-positive bacterium. To transform this enzyme into a tool capable of attacking E. coli, the team made two specific changes. First, they fused a short, ten-amino-acid chain to the front of the enzyme. This chain is rich in positive charges, designed to act like a key that can interact with the negatively charged surface of the Gram-negative outer membrane. Second, they made two tiny adjustments to the enzyme's internal structure, swapping specific building blocks to potentially improve how it grips its target. The result was a new, engineered protein they named ArtE2.
The researchers then put this new creation to the test in the laboratory. They grew cultures of both E. coli and Staphylococcus aureus and exposed them to the protein. The results were striking. The original, unmodified enzyme had almost no effect on the E. coli, failing to reduce the number of living bacteria. In contrast, the engineered ArtE2 proved highly effective, reducing the population of E. coli by a factor of one million within an hour. Crucially, the new protein not only retained its original power against Staphylococcus aureus but also resulted in lower residual counts of surviving bacteria after treatment compared to the natural version. The team also observed that the protein's ability to kill bacteria depended on how much of it was present and how long the bacteria were exposed to it, suggesting a direct and controllable relationship between the treatment and the outcome.
To understand why this new design worked, the scientists looked at the protein's behavior using computer simulations. They modeled how the protein might interact with the fragments that make up the bacterial cell wall. These simulations suggested that the engineered protein binds more tightly to these fragments than the original version did, particularly under specific conditions involving calcium ions and a neutral pH level. The computer models also showed that the protein remained stable and held its shape well under these conditions, which aligns with the experimental results showing strong antibacterial activity. However, the researchers were careful to note that these computer models are predictions, not direct measurements of binding strength, and that the exact mechanism by which the protein breaches the outer membrane of the Gram-negative bacteria was not directly observed in this study.
The study concludes that this engineering approach successfully expanded the range of a natural enzyme to include a difficult Gram-negative target while keeping its effectiveness against Gram-positive bacteria. The work provides a proof of concept that modifying these enzymes with charged peptides and small structural tweaks can overcome natural barriers. While the results are promising, the authors emphasize that this was a preliminary study using standard laboratory strains of bacteria. They suggest that the next step is to test this engineered protein against a wider variety of bacteria, including those that are resistant to current antibiotics, to fully determine its potential as a new type of antibacterial agent. For now, the research offers a clear path forward: by carefully redesigning nature's tools, scientists may be able to create new defenses against the growing threat of drug-resistant infections.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.